BAMCO Inc
CBAY

BAMCO Inc’s Cymabay Therapeutics CBAY Stock Holding History

BAMCO Inc’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-44,206
Closed -$385K – 366
2023
Q1 		$385K Sell
44,206
-28,389
-39% -$227K ﹤0.01% 341
2022
Q4 		$455K Buy
+72,595
New +$276K ﹤0.01% 348

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BAMCO Inc's CBAY Position: Q2 2023 in Review

BAMCO Inc sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 44,206 shares — an estimated $385K sold.

BAMCO Inc first reported a position in CBAY in Q4 2022 and held it in 2 quarters. The position peaked at $455K in Q4 2022. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

  • BAMCO Inc reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
  • BAMCO Inc sold 44,206 Cymabay Therapeutics shares in Q2 2023, an estimated $385K.
  • BAMCO Inc first reported a position in Cymabay Therapeutics in Q4 2022 and held it in 2 quarters.
  • BAMCO Inc's Cymabay Therapeutics position peaked at $455K in Q4 2022.
  • 151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on BAMCO Inc's 13F filing for Q2 2023, filed 14 Aug 2023.